The upcoming Biomarker AGORA has full house when it comes to exhibition booths – 76 companies and university projects will be displayed along with pitching sessions and key-notes given by a Dutch and an American guest speaker respectively
Professor Alain van Gool
Professor of Personalized Healthcare at Radboud University Medical Center in the Netherlands Alain van Gool has a professional background, which is a mix of academia, pharmaceutical industry, applied research institutes, university medical centers. He has been leading technology-based biomarker laboratories, cross-functional expert teams, therapeutic project teams and public-private consortia, many of which were focused on the discovery, development and implementation of translational biomarkers in a variety of therapeutic areas. While working in Europe, USA and Asia, he and his teams contributed to over 200 projects in various phases of biomarker R&D.
Alain is a strong believer of open innovation networks and in his roles he has been collaborating with pharmaceutical, biotechnological, nutriceutical and diagnostic industries, SMEs, biobanks, clinicians, technology providers and information specialists to translate basic research to applied science through public-private partnerships. With that background, he currently heads the Radboudumc center for proteomics, glycomics & metabolomics, coordinates the Radboudumc Technology Centers, is Scientific Lead Technologies of DTL (the Dutch Techcenter for Life Sciences) and is chair Biomarker Platform of EATRIS (the European infrastructure for Translational Medicine), thus contributing to the organisation and coordination of local, national and European technology infrastructures.
Contributing writer at New York Times Pagan Kennedy
Pagan Kennedy is deeply interested in user driven innovation and is author of 11 books and a number of articles published in dozens of magazines and newspapers.
Pagan Kennedy's autobiographical zine Pagan's Head detailed her life during her twenties. She wrote a biography called The First Man-Made Man about Michael Dillon who in the 1940s was the first successful case of female-to-male sex change treatment; he established himself as a medical student. It describes how he later fell in love with a male-to-female transsexual, Roberta Cowell, who was at the time the only other transsexual in Britain.
Pagan Kennedy was a visiting professor of creative writing at Dartmouth College, and taught fiction and nonfiction writing at Boston College, Johns Hopkins University, and many other conferences and residencies.
Pagan Kennedy has been an MIT Knight Science Journalism fellow and received several awards including a Smithsonian fellowship, a Massachusetts Book Prize honor in nonfiction, and a National Endowment for the Arts fellowship. In 2012, Pagan Kennedy was named design columnist for the New York Times Magazine. Her column, "Who Made That," detailed the origins of everything from the cubicle to the home pregnancy test. Kennedy resigned from the column after signing a contract with Houghton Mifflin Harcourt to write a book, Inventology.
Pagan Kennedy has a huge interest in userdriven innovation, including women led innovation. Pagan Kennedy talks about ’Democratizing Invention: Why Users Often Know Best’ referring to two columns published in New York Times Magazine this year: ’Tampon of the Future’, and ’Could women be trusted with their own pregnancy tests’.
Menstrual tampons as test tools – is that possible?
At the Biomarker AGORA 2016 many questions about the use of biomarkers will beclarified and also whether you can use menstrual tampons as diagnostic tools.
The AGORA takes place at 1 November from 10.00 – 15.00 in ’Marmorhallen’ at the University of Copenhagen, Campus Frederiksberg, Thorvaldsensvej 40, 1871 Frederiksberg C. Everybody with aninterest in the biomarker field are welcome.
The Biomarker AGORA is hosted by Biopeople incollaboration with the University of Copenhagen and Denmark’s Technical University, and sponsoredby Bioneer, Høiberg, Jusmedico and Pharmadanmark.
Biomarkers are key to the development of personalized medicine, a treatment paradigm, which isdeveloping rapidly. Concurrently there is a growing need to increase focus on the number of biomarkers that become available.
Biomarker AGORA offers key-notes, researchers and companies that pitch projects to the audienceas well as exhibition booths displaying university and company projects. Patient organizations arealso present, representing the end-users of personalized medicine.
Tamponer som testværktøj - kan man det?
Hvorvidt man kan anvende en menstruationstampon som diagnostisk redskab og mange andre spørgsmål om brug af biomarkører bliver belyst på Biomarker AGORA 2016.
Den finder sted 1 november fra 10.00 – 15.00 i Marmorhallen på Københavns Universitet Campus Frederiksberg, Thorvaldsensvej 40, 1871 Frederiksberg C. Alle med interesse i biomarkørfeltet er velkomne til at deltage på Biomarker AGORA, der er arrangeret af Biopeople i samarbejde med Københavns Universitet og DTU, og sponsoreret af GTS Instituttet Bioneer, Høiberg, Jusmedico og Pharmadanmark.
Biomarkører er nøglen til udviklingen af skræddersyet behandling, et behandlingsparadigme, som er i rivende udvikling. Samtidig er der et stigende behov for at skærpe fokus på omfanget af biomarkører, der bliver tilgængelige.
Biomarker AGORA byder på nøgleforedrag, forskere og virksomheder, der pitcher projekter for publikum samt udstillinger af universitets- og virksomhedsprojekter. Derudover deltager patientforeninger, som repræsentanter for brugerne af den skræddersyede behandling.
Projektleder Randi Krogsgaard